Pfizer Inc. (PFE) and Zhejiang Hisun Pharmaceuticals announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies.
Hisun-Pfizer has an aggregate investment of $295 million and a registered capital of $250 million. Hisun holds 51% of the share and Pfizer holds 49%. Hisun-Pfizer plans aims to provide high-quality and affordable branded generic medicines for patients in China and global markets.
Both the companies stated that Hisun-Pfizer will take advantage of Hisun's strong product portfolio, broad market outreach and experience with the production and commercialization of branded generic medicines.
The joint venture will also benefit from Pfizer's R&D, manufacturing quality management, international market promotion and operational capabilities. It will focus on R&D and production and commercialization of branded generic medicines, and broader commercialization of existing medicines.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.